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Protective effect of intranasal vaccination of horses
with a modiﬁed live equine herpesvirus type 1 vaccine
H. Bannai*, M. Nemoto, K. Tsujimura, T. Yamanaka, T. Kondo
Epizootic Research Center, Equine Research Institute, Japan
Racing Association, Shimotsuke, Tochigi, Japan
Mucosal immunity in the nasal cavity is considered to play an
essential role in protecting horses from disease caused by equine
herpesvirus type 1 (EHV-1), and immunoglobulin A (IgA) anti-
body in the nasal secretions is a key component of this mucosal
immunity. Although intranasal administration of live or killed
EHV-1 vaccines has been attempted with the aim of protecting
horses from viral challenge, induction of virus-speciﬁc IgA after
these vaccinations was not observed, and only slight mitigation of
clinical signs was observed after viral challenge. Here, we
measured immunological responses and performed a challenge
experiment in horses intranasally immunized with a modiﬁed
live EHV-1 vaccine (Nisseiken, Tokyo, Japan) that was originally
licensed for intramuscular injection. Horses (n ¼ 3) were intra-
nasally inoculated with the vaccine (1.3 106 plaque-forming units
[pfu]/10 mL/head) twice with a 4-week interval. Control horses (n
¼ 2) were inoculated in the samewaywith dilutionmedium. Four
weeks after the second dose had been given, the horses were
challenged by intranasal inoculation of EHV-1 (strain 10-I-224,
4.0 106 pfu/10 mL/head). Sequential nasal wash samples were
concentrated by ultraﬁltration and subjected to ELISA to measure
EHV-1-speciﬁc IgA. Viral nasal shedding and viremia were
monitored by virus isolation and real-time PCR. The results of
real-time PCR were considered negative if there were 10 gene
copies in the analyzed sample. EHV-1-speciﬁc IgA levels in the
nasal wash increased in all of the vaccinated horses after two
intranasal doses of vaccine, whereas those in the control horses
remained stable. Serum virus-neutralizing titers also increased in
the vaccinated horses. After viral challenge, pyrexia over 39.0 C
was observed at 1 day post-inoculation (dpi) in both of the control
horses. In contrast, none of the vaccinated horses was pyretic
(over 39.0 C) throughout the experiment, although one horse
had a temperature of 38.7 C at 7 dpi. Viral nasal shedding in the
control horses was detected at 1 to 6 dpi, with a highest mean
gene copy number of 103.8. In contrast, viral nasal shedding in the
vaccinated horses was detected only at 1 to 2 dpi, with a highest
mean gene copy number of 102.3. Viremia was detected in all
horses at 5 to 11 dpi, with individual durations of 2 to 6 days.
Intranasal immunization of horses with the live EHV-1 vaccine
resulted in the production of EHV-1-speciﬁc IgA in the nasal
mucosa and virus-neutralizing antibody in the whole body. Virus
replication in the nasal mucosa after viral challenge was lower in
vaccinated horses than in control horses; virus-speciﬁc IgA0737-0806/$ e see front matter.induced by the intranasal vaccination might have been respon-
sible for this. The absence of pyrexia over 39.0 C in the vaccinated
horses indicated that the immunity induced by intranasal vacci-
nation was effective in protecting horses from EHV-1-induced
pyrexia.
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Equine herpesvirus type 1 (EHV-1) conquers and
reprograms mononuclear cells to ensure transfer to
endothelial cells
Walid Azab, Klaus Osterrieder
Institut für Virologie, Zentrum für Infektionsmedizin, Freie
Universit€at Berlin, Robert-von-Ostertag-Str. 7-13, 14163 Berlin,
Germany
Equine herpesviruses 1 and 4 (EHV-1 and EHV-4) are members of
the Alphaherpesvirinae subfamily and belong to the genus Vari-
cellovirus. Both viruses are endemic in horse populations
throughout the world and cause severe economic losses. Both vi-
ruses cause respiratory disease; however, only EHV-1 can efﬁ-
ciently transfer fromperipheral bloodmononuclear cells (PBMC) to
endothelial cells lining the blood vessels of the pregnant uterus or
central nervous system, the prerequisite for abortion, perinatal
mortality and neurological disorders (myeloencephalopathy).
EHV-4 can also infect both PBMC and endothelial cells in culture
but does not cause any of the severe complications. We were
interested in studying the differences between EHV-1 and EHV-4
infection of PBMC and how it affects PBMC-endothelial interaction
and disease outcome. Our results indicate that EHV-1 infects B-
lymphocyte and monocyte subpopulations more efﬁciently than
EHV-4. In order to evaluate viral transfer between infected PBMC
and endothelial cells, co-cultivation assays were performed in the
presence of virus neutralizing antibodies. Only EHV-1 was able to
transfer to endothelial cells and viral glycoprotein B (gB) was
shown to be important for this form of cell-to-cell transfer. For
addressing the more dynamic aspects of the interaction, infected
PBMC were allowed to ﬂow (0.5 mm/sec) over endothelial cell
monolayers in the presence of virus neutralizing antibodies. By
simulating the capillary blood ﬂow and analyzing the behavior of
infected PBMC through live ﬂuorescence imaging and automated
cell tracking, we observed that EHV-1 was able to maintain teth-
ering and rolling of infected PBMC more effectively than EHV-4.
Deletion of US3 reduced the ability of infected PBMC to tether and
roll compared to parental virus, which resulted in a signiﬁcant
reduction in virus transfer. We further investigated the expression
and regulation of various adhesion molecules on the surface of
EHV-1 and EHV-4-infected PBMCs. We found that EHV-4, in
contrast to EHV-1, was able to downregulate VLA-4 and LFA-1
adhesion molecules on the surface of infected PBMC. These
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infected PBMC to adhere to endothelial cells and therefore
decrease the probability of infection due to the absence of viral
transfer between EHV-4-infected PBMC and endothelial cells. We
were able to show that the EHV-4 UL56 in comparison to its
counterpart in EHV-1 was able to downregulate VLA-4 on equine
dermal cells. Taken together, we conclude that systemic spread and
higher pathogenic potential of EHV-1 compared to EHV-4 is caused
by differences in their abilities to infect and/or reprogram mono-
nuclear cells with respect to virus transfer to endothelial cells.
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Antibody and cellular immune responses of naïve mares
to repeated vaccination with an inactivated equine
herpesvirus vaccine
B. Wagner, L.B. Goodman, S. Babasyan, H. Freer, S.
Torsteinsdottir, V. Svansson, S. Bj€ornsdottir, G.A. Perkins*
College of Veterinary Medicine, Cornell University, Ithaca, NY
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Equine herpesvirus type 1 (EHV-1) continues to cause severe
outbreaks of abortions and myeloencephalopathy in horses
despite widely used vaccination. The aim of this work was to
determine the effects of frequent vaccination with an inactivated
EHV vaccine on immune development in horses. Fifteen EHV-1
naïve mares were vaccinated a total of 5 times over a period of 8
months with intervals of 20, 60, 90 and 60 days between vaccine
administrations. Total antibody and antibody isotype responses
were evaluated with a new sensitive EHV-1 Multiplex assay to
glycoprotein C (gC) and gD for up to 14 months after initial
vaccination. Antibodies peaked after the ﬁrst two vaccine doses
and then declined despite a third administration of the vaccine.
The fourth vaccine dose was given at 6 months and the gC and gD
antibody titers increased again. Mixed responses with increasing
gC but decreasing gD antibody values were observed after the
ﬁfth vaccination at 8 months. IgG4/7 isotype responses mimicked
the total Ig antibody production to vaccination most closely.
Vaccination also induced short-lasting IgG1 antibodies to gC, but
not to gD. EHV-1-speciﬁc cellular immunity induced by vaccina-
tion developed slower than antibodies, was dominated by IFN-g
producing T-helper 1 (Th1) cells, and was signiﬁcantly increased
compared to pre-vaccination values after administration of 3
vaccine doses. Decreased IFN-g production and reduced Th1-cell
induction were also observed after the second and fourth vacci-
nation. Overall, repeated EHV vaccine administration did not al-
ways result in increasing immunity. The adverse effects on
antibody and cellular immunity that were observed here when
the EHV vaccine was given in short intervals might in part explain
why EHV-1 outbreaks are observed despite widely used vacci-
nation. The ﬁndings warrant further evaluation of immune re-
sponses to EHV vaccines to optimize vaccination protocols for
different vaccines and horse groups at risk.
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Equine Herpesvirus-1 Interferes with Type-I IFN-
Mediated Immune Responses in vitro in Equine
Endothelial Cells
S. Sarkar, U.B.R. Balasuriya, D.W. Horohov, T.M. Chambers
Department of Veterinary Science, Maxwell H. Gluck Equine
Research Center, University of Kentucky, Lexington, KY 40546,
USA
Equine herpesvirus-1 (EHV-1) is one of the major viral pathogens
of equids causing respiratory disease, abortion and neurologicdisease. Recently, there have been increasing incidences of
neurologic disease caused by EHV-1 in many countries. Type-I
interferon (IFN) is considered to be the ﬁrst line of defense against
many viral pathogens. It has been reported earlier that EHV-1
infects the endothelial cells lining the blood vessels of the central
nervous system and induces vasculitis leading to neurologic signs
in horses. We have previously shown that the neuropathogenic
T953 strain of EHV-1 suppresses type-I IFN in equine endothelial
cells (EECs) (Sarkar et al., 2015). However, the antiviral effect of
type-I IFN in the endothelial cells has not been studied in detail.
We hypothesized that EHV-1 infection inhibits type-I IFN-
mediated antiviral response. In this study we investigated the
antiviral effect of type-I IFN against the neuropathogenic T953
strain of EHV-1 in vitro in EECs. To study the effect of type-I IFN,
sub-conﬂuent monolayers of EECs were stimulated with puriﬁed
recombinant equine IFN-a (rEqIFN-a) for 24 h before infecting
with T953 strain of EHV-1 or vesicular stomatitis virus expressing
green ﬂuorescent protein (VSV-GFP) at an MOI¼0.1. VSV-GFP was
used as a positive control for IFN-sensitive virus. At different
times post infection (pi), cell supernatants were collected and
titrated by plaque assay on rabbit kidney-13 cells to determine
the number of virus particles. In a separate experiment, rEqIFN-a-
treated EECs were resuspended into single cell suspensions and
an infectious center assay was performed to determine if rEqIFN-
a interfered with the infectivity of the IFN-treated cells. The re-
sults from both of the experiments demonstrated that T953 strain
of EHV-1 was partially resistant to the antiviral effect of exoge-
nously supplied rEqIFN-a. To investigate the mechanism of
resistance, the effects of EHV-1 infection on JAK-STAT signaling
pathways were analyzed. Conﬂuent monolayers of EECs were
infected with T953 strain of EHV-1 at an MOI of 5.0 and at
different times pi (3 h and 12 h), cells were stimulated with
rEqIFN-a 30 min prior to lysis for Western blotting analysis to
determine the level of endogenous as well as phosphorylated
STAT-1. Mock infected EECs stimulated with rEqIFN-a or MEM
were used as either positive or negative controls, respectively. The
results demonstrated that the virus infection not only interfered
with STAT-1 phosphorylation, but also suppressed exogenous
rEqIFN-a-induced STAT-1 phosphorylation. The ﬁndings were
further conﬁrmed by indirect immunoﬂuorescence assay which
showed that EHV-1 T953 strain prevented rEqIFN-a-induced
nuclear translocation of STAT-1 from cytoplasm. Furthermore,
this study also revealed that downstream of the JAK-STAT
signaling, EHV-1 infection inhibited expression of cellular anti-
viral proteins including IFN-stimulated gene 56 (ISG56) and
viperin. Altogether these data show that the neuropathogenic
T953 strain of EHV-1 evades the host innate immune response by
inhibiting the type-I IFN signaling pathway in EECs.
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Changes in clinical parameters, SAA concentrations and
virus-neutralising antibody titres after EHV-1
vaccination in mules and horses
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